Karmakar Souvik, Reilly Karlyne M
Rare Tumors Initiative, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 37 Convent Dr, Bethesda, MD 20814, USA.
CNS Oncol. 2017 Jan;6(1):45-60. doi: 10.2217/cns-2016-0024. Epub 2016 Dec 21.
With the recent development of new anticancer therapies targeting the immune system, it is important to understand which immune cell types and cytokines play critical roles in suppressing or promoting tumorigenesis. The role of mast cells in promoting neurofibroma growth in neurofibromatosis type 1 (NF1) patients was hypothesized decades ago. More recent experiments in mouse models have demonstrated the causal role of mast cells in neurofibroma development and of microglia in optic pathway glioma development. We review here what is known about the role of NF1 mutation in immune cell function and the role of immune cells in promoting tumorigenesis in NF1. We also review the therapies targeting immune cell pathways and their promise in NF1 tumors.
随着近期针对免疫系统的新型抗癌疗法的发展,了解哪些免疫细胞类型和细胞因子在抑制或促进肿瘤发生中起关键作用非常重要。几十年前就有人推测肥大细胞在1型神经纤维瘤病(NF1)患者的神经纤维瘤生长中起促进作用。最近在小鼠模型中的实验已经证明了肥大细胞在神经纤维瘤发展中的因果作用以及小胶质细胞在视神经通路胶质瘤发展中的因果作用。我们在此回顾关于NF1突变在免疫细胞功能中的作用以及免疫细胞在促进NF1肿瘤发生中的作用的已知情况。我们还回顾了针对免疫细胞途径的疗法及其在NF1肿瘤中的前景。